Aeterna Zentaris (AEZS) Competitors $3.56 +0.02 (+0.56%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends AEZS vs. BGXX, GLYC, RNXT, IBIO, ATHA, TPST, PIRS, SPRB, UBX, and APREShould you be buying Aeterna Zentaris stock or one of its competitors? The main competitors of Aeterna Zentaris include Bright Green (BGXX), GlycoMimetics (GLYC), RenovoRx (RNXT), iBio (IBIO), Athira Pharma (ATHA), Tempest Therapeutics (TPST), Pieris Pharmaceuticals (PIRS), Spruce Biosciences (SPRB), Unity Biotechnology (UBX), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Aeterna Zentaris vs. Bright Green GlycoMimetics RenovoRx iBio Athira Pharma Tempest Therapeutics Pieris Pharmaceuticals Spruce Biosciences Unity Biotechnology Aprea Therapeutics Bright Green (NASDAQ:BGXX) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends. Does the media prefer BGXX or AEZS? In the previous week, Bright Green's average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score. Company Overall Sentiment Bright Green Neutral Aeterna Zentaris Neutral Does the MarketBeat Community favor BGXX or AEZS? Aeterna Zentaris received 419 more outperform votes than Bright Green when rated by MarketBeat users. CompanyUnderperformOutperformBright GreenN/AN/AAeterna ZentarisOutperform Votes41960.37% Underperform Votes27539.63% Which has better earnings and valuation, BGXX or AEZS? Bright Green has higher earnings, but lower revenue than Aeterna Zentaris. Bright Green is trading at a lower price-to-earnings ratio than Aeterna Zentaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright GreenN/AN/A-$13.13M-$0.06-2.17Aeterna Zentaris$2.37M2.69-$16.55M-$14.86-0.24 Which has more risk & volatility, BGXX or AEZS? Bright Green has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Do institutionals & insiders hold more shares of BGXX or AEZS? 7.8% of Bright Green shares are owned by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are owned by institutional investors. 62.6% of Bright Green shares are owned by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BGXX or AEZS more profitable? Bright Green has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Bright Green's return on equity of -83.40% beat Aeterna Zentaris' return on equity.Company Net Margins Return on Equity Return on Assets Bright GreenN/A -83.40% -53.83% Aeterna Zentaris -760.32%-83.45%-45.76% Do analysts recommend BGXX or AEZS? Aeterna Zentaris has a consensus target price of $60.00, suggesting a potential upside of 1,585.39%. Given Aeterna Zentaris' higher possible upside, analysts clearly believe Aeterna Zentaris is more favorable than Bright Green.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Green 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAeterna Zentaris 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAeterna Zentaris beats Bright Green on 7 of the 13 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get Aeterna Zentaris News Delivered to You Automatically Sign up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEZS vs. The Competition Export to ExcelMetricAeterna ZentarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.38M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E Ratio-0.249.36112.5515.07Price / Sales2.69386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book0.245.324.645.01Net Income-$16.55M$153.56M$119.13M$225.46M7 Day Performance-3.52%0.12%0.78%0.37%1 Month Performance-6.32%15.23%5.65%3.57%1 Year Performance-37.32%41.16%36.90%29.42% Aeterna Zentaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEZSAeterna ZentarisN/A$3.56+0.6%$60.00+1,585.4%-39.0%$6.38M$2.37M-0.2420Analyst ForecastGap UpBGXXBright GreenN/A$0.13-7.1%N/A-63.5%$24.85MN/A-2.172Gap DownGLYCGlycoMimetics4.3859 of 5 stars$0.38-5.0%$10.00+2,513.7%-69.6%$24.67M$10,000.00-0.6650Analyst ForecastOptions VolumeNews CoverageRNXTRenovoRx1.6731 of 5 stars$1.02+2.0%$6.13+500.5%-3.8%$24.47MN/A-1.706Positive NewsIBIOiBio1.0468 of 5 stars$2.67+3.1%$4.30+61.0%N/A$24.40M$225,000.000.00100ATHAAthira Pharma2.5581 of 5 stars$0.61+42.3%$13.83+2,183.1%-65.4%$23.29MN/A-0.2040Gap UpHigh Trading VolumeTPSTTempest Therapeutics2.245 of 5 stars$0.91-1.1%$20.75+2,181.7%-75.4%$23.07MN/A-0.5720PIRSPieris Pharmaceuticals2.3762 of 5 stars$17.30+0.3%N/A-14.4%$22.77M$42.81M-0.92140Gap DownSPRBSpruce Biosciences3.0101 of 5 stars$0.55+3.8%$5.00+812.1%-51.1%$22.64M$10.09M-0.5320UBXUnity Biotechnology3.9281 of 5 stars$1.31-3.7%$6.67+408.9%-29.2%$22.07M$240,000.00-0.6660Positive NewsAPREAprea Therapeutics3.5958 of 5 stars$3.92+0.3%$15.50+295.4%+13.3%$21.29M$580,000.00-1.297Short Interest ↑ Related Companies and Tools Related Companies BGXX Alternatives GLYC Alternatives RNXT Alternatives IBIO Alternatives ATHA Alternatives TPST Alternatives PIRS Alternatives SPRB Alternatives UBX Alternatives APRE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AEZS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
